Alignment Healthcare (ALHC) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alignment Healthcare (ALHC) has outperformed YD Bio (YDES) over the past year, losing 50.8% versus a loss of 66.1%. Alignment Healthcare is the larger company by market cap ($1.54 billion vs $479.5 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALHC | YDES |
|---|---|---|
| Share price | $7.43 | $6.77 |
| Market cap | $1.54B | $479.53M |
| 1-day change | -14.67% | +16.93% |
| YTD return | -55.90% | -52.50% |
| 1-year return | -50.76% | -66.06% |
| 5-year return | -53.22% | — |
| P/E ratio (TTM) | 39.12 | — |
| Forward P/E | 10.11 | — |
| EPS (TTM) | $0.19 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.95B | — |
| Revenue growth (YoY) | +46.06% | — |
| Net income (latest FY) | $-724.00K | — |
| Operating margin | 0.37% | — |
| Net margin | -0.02% | — |
| 52-week high | $25.12 | $22.00 |
| 52-week low | $6.01 | $1.70 |
| Distance from 52-week high | -70.41% | -69.23% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +176.34% | — |
| Average volume | 7.55M | 284.92K |
| Shares outstanding | 207.44M | 70.83M |
| Employees | 1,849 | 13 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alignment Healthcare is about 3.2 times larger than YD Bio by market value ($1.54B vs $479.53M).
- ALHC has outperformed YDES by 15.3 percentage points over the past year.
About Alignment Healthcare
ALHC stock →Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States.
Health Care · Medical Specialities · 1,849 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
ALHC vs YDES FAQ
Which is bigger, Alignment Healthcare or YD Bio?
Alignment Healthcare (ALHC) is larger, with a market capitalization of $1.54B compared with $479.53M for YD Bio (YDES).
Which stock has performed better over the past year, ALHC or YDES?
ALHC returned -50.76% over the past 12 months, compared with -66.06% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Alignment Healthcare and YD Bio in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.